ProQR Therapeutics (PRQR) Competitors $2.29 +0.04 (+1.78%) Closing price 04:00 PM EasternExtended Trading$2.34 +0.05 (+2.36%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. UPB, ORIC, PHAR, TRVI, URGN, IMNM, QURE, SANA, AKBA, and PHATShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Upstream Bio (UPB), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Trevi Therapeutics (TRVI), Urogen Pharma (URGN), Immunome (IMNM), uniQure (QURE), Sana Biotechnology (SANA), Akebia Therapeutics (AKBA), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Its Competitors Upstream Bio Oric Pharmaceuticals Pharming Group Trevi Therapeutics Urogen Pharma Immunome uniQure Sana Biotechnology Akebia Therapeutics Phathom Pharmaceuticals ProQR Therapeutics (NASDAQ:PRQR) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do analysts prefer PRQR or UPB? ProQR Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 249.34%. Upstream Bio has a consensus target price of $56.50, indicating a potential upside of 178.87%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe ProQR Therapeutics is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer PRQR or UPB? In the previous week, Upstream Bio had 4 more articles in the media than ProQR Therapeutics. MarketBeat recorded 8 mentions for Upstream Bio and 4 mentions for ProQR Therapeutics. Upstream Bio's average media sentiment score of 1.18 beat ProQR Therapeutics' score of 0.75 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PRQR or UPB more profitable? ProQR Therapeutics has a net margin of -238.52% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-238.52% -61.25% -28.13% Upstream Bio -3,836.58%-35.90%-26.26% Which has preferable valuation and earnings, PRQR or UPB? ProQR Therapeutics has higher revenue and earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$20.46M11.78-$30.04M-$0.46-4.98Upstream Bio$2.72M401.10-$62.81MN/AN/A Do institutionals and insiders have more ownership in PRQR or UPB? 32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryProQR Therapeutics beats Upstream Bio on 8 of the 14 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.93M$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-4.9820.9982.6526.40Price / Sales11.78396.26529.10204.59Price / CashN/A43.5325.7028.92Price / Book2.529.8811.246.06Net Income-$30.04M-$53.38M$3.28B$266.05M7 Day Performance4.09%-0.14%0.15%-0.07%1 Month Performance10.10%9.18%8.36%5.83%1 Year Performance13.37%7.53%54.25%17.89% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.4171 of 5 stars$2.29+1.8%$8.00+249.3%+11.4%$240.93M$20.46M-4.98180UPBUpstream Bio2.1329 of 5 stars$16.73-5.1%$56.50+237.7%N/A$950.42M$2.37M0.0038News CoveragePositive NewsORICOric Pharmaceuticals4.5476 of 5 stars$9.62-1.2%$17.63+83.2%-1.4%$945.98MN/A-5.0980News CoveragePHARPharming Group3.0103 of 5 stars$14.28+4.2%$30.00+110.1%+93.0%$938.65M$297.20M-109.85280News CoveragePositive NewsShort Interest ↓Gap DownTRVITrevi Therapeutics2.1429 of 5 stars$7.28-3.6%$20.11+176.3%+129.7%$919.42MN/A-17.3320News CoveragePositive NewsURGNUrogen Pharma4.5641 of 5 stars$18.50-4.8%$32.00+73.0%+39.8%$899.38M$90.40M-5.57200Positive NewsIMNMImmunome2.0552 of 5 stars$9.92-3.7%$22.50+126.8%-37.4%$896.56M$12.59M-3.2240Positive NewsQUREuniQure2.2934 of 5 stars$15.55-1.0%$37.45+140.9%+179.1%$861.41M$27.12M-3.97500News CoverageSANASana Biotechnology2.3191 of 5 stars$3.35-6.4%$8.00+138.8%-49.4%$851.35MN/A-3.16380AKBAAkebia Therapeutics3.5881 of 5 stars$3.03-5.0%$6.75+122.8%+102.6%$845.81M$160.18M-17.82430Positive NewsGap DownPHATPhathom Pharmaceuticals2.8404 of 5 stars$11.57-2.9%$17.50+51.3%-26.3%$844.94M$114.04M-2.45110News Coverage Related Companies and Tools Related Companies Upstream Bio Competitors Oric Pharmaceuticals Competitors Pharming Group Competitors Trevi Therapeutics Competitors Urogen Pharma Competitors Immunome Competitors uniQure Competitors Sana Biotechnology Competitors Akebia Therapeutics Competitors Phathom Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
